Pet Pharm Biotech Co., Ltd. (TPEX:7762)

Revenue by Product

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Nuclear Medicine	124.23M
Nuclear Medicine Growth	6.19%
Other	6.47M
Other Growth	643.33%

Revenue by Geography

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Taiwan	130.70M
Taiwan Growth	10.89%